Fertility Clinics in European Union 2026: Industry Statistics & Trends

The fertility clinics industry in the European Union provides medically assisted reproductive therapies, such as in vitro fertilization (IVF) and frozen embryo transfers, to individuals and couples facing infertility or seeking reproductive preservation. Driven by a structural decline in natural birth rates and an upward shift in the average age of first-time mothers, the market has expanded into a major specialized healthcare sector. The European IVF Monitoring (EIM) Consortium reported a total of 1,156,316 assisted reproductive technology (ART) treatment cycles across Europe in 2023 (European Society of Human Reproduction and Embryology), highlighting the substantial scale of clinical dema

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Fertility Clinics in European Union industry cover?

The industry encompasses private clinics, specialized hospital departments, and dedicated laboratories that deliver medically assisted reproduction services. These services include diagnostic infertility assessments, ovulation induction, artificial insemination, in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and embryo cryopreservation. The industry also includes related activities such as egg and sperm donation management and pre-implantation genetic testing.

• •Primary clinical procedures tracked by European authorities include IVF, ICSI, and frozen embryo transfers (FET).
• •Clinical operations fall under the broad healthcare classification systems, specifically tracking medical practices and specialized clinical laboratories.
• •Services increasingly cover fertility preservation techniques such as oocyte and embryo vitrification.

Who operates in the industry and how is it structured?

The European Union fertility market is characterized by a mix of public university hospital departments and highly commercialized private clinic networks. Private operators command a dominant share of treatment volumes in several member states, driven by cross-border reproductive care and varying levels of public healthcare reimbursement. Geographic distribution is uneven, with countries featuring liberal regulatory frameworks, such as Spain, capturing a disproportionately large share of total European treatment cycles.

• •Data from 2023 tracked by the EIM Consortium represented 1,473 active fertility centers across 36 European nations.
• •Spain acts as a major regional hub, accounting for an estimated 22.6% of the European fertility market according to data compiled in 2024.
• •The market features a dual-operating model where patients navigate between heavily subsidized public health routes and out-of-pocket private clinics.

What drives demand in the industry?

The industry's expansion is heavily supported by demographic shifts, notably the continuous postponement of childbearing and falling natural fertility indicators. Eurostat data indicates that the average age of women giving birth to their first child reached 29.9 years in 2024. Concurrently, public acceptance and institutional support for medical intervention remain robust, driving steady patient inflows into reproductive healthcare facilities.

• •The total fertility rate in the European Union hit a historical low of 1.34 live births per woman in 2024 (Eurostat).
• •Specific member states exhibit acute 'lowest-low fertility' levels, with 2024 rates dropping to 1.10 in Spain and 1.01 in Malta.
• •A 2026 Europe-wide public attitude survey backed by ESHRE indicated that a majority of citizens support state-funded fertility treatments, ranging from 54% in the Netherlands to 64% in Italy.

Who are the notable companies in the industry?

The European fertility clinic landscape is highly competitive, increasingly shaped by corporate investment groups and multinational healthcare operators. While many individual practices remain standalone, several large corporate networks and publicly traded medical technology firms support or directly manage extensive clinic portfolios. Key market participants include international clinical networks and reproductive genetics companies operating across multiple EU borders.

• •Vitrolife AB (Vitrolife Group) is a prominent publicly listed medical device and genetic testing corporation heavily integrated into European IVF clinics.
• •Merck KGaA and Bayer AG operate as major pharmaceutical and biotech suppliers providing hormonal therapies and fertility treatments across EU clinics.
• •Evident corporate networks and specialized clinical operations across major jurisdictions include groups like Igenomix (integrated under Vitrolife) and large private provider networks operating across Spain, Germany, and Italy.
• •Clinical competition increasingly focuses on technological success rates, such as optimizing culture media and implementing advanced embryo selection.

What are the recent trends and outlook?

A defining operational trend in the industry is the rapid rise of frozen embryo transfers (FET) relative to fresh cycles, optimizing patient safety and clinical workflows. Out of the total cycles monitored in 2023, FET accounted for nearly 43% of all treatment variations, totaling 401,483 cycles. Clinical guidelines are successfully enforcing single-embryo transfers to drastically reduce multiple gestations, resulting in the lowest twin and triplet delivery rates in decades.

• •In 2023, preliminary data recorded 158,649 standard IVF cycles and 388,345 ICSI cycles across reporting European centers.
• •Crude cumulative live birth rates have shown a steady upward trend due to improved laboratory vitrification protocols.
• •More than 32,000 fertility preservation procedures were officially registered in 2023, highlighting an expanding elective market.

How is the industry regulated?

Regulatory frameworks governing fertility clinics in the EU are highly fragmented, as ethical and legal boundaries are determined at the national level rather than through centralized EU mandates. Member states enforce strict guidelines on aspects such as egg donation anonymity, access criteria for single or same-sex individuals, and pre-implantation screening limits. Laboratories must comply with rigorous quality and safety standards for the handling of human tissues and cells.

• •The European Society of Human Reproduction and Embryology (ESHRE) works to harmonize clinical practices, laboratory standards, and ethical guidelines across borders.
• •National laws create substantial medical tourism, as prohibited treatments in one state (such as embryo research bans in Italy) push patients to permissive jurisdictions like Spain or the Netherlands.
• •Clinics face strict mandates regarding complication reporting; in 2023, 1,760 cases of ovarian hyperstimulation syndrome (OHSS) were officially documented.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat Fertility Statistics 2024 ·
• European Society of Human Reproduction and Embryology (ESHRE) EIM Consortium 2023 Preliminary Data ·
• Progress Educational Trust & ESHRE Public Attitudes Survey Report 2026